Literature DB >> 21316271

The burden of symptoms predicts early retirement: a twin cohort study on fibromyalgia-associated symptoms.

Ritva Markkula1, Eija Kalso, Antti Huunan-Seppälä, Markku Koskenvuo, Karoliina Koskenvuo, Päivi Leino-Arjas, Jaakko Kaprio.   

Abstract

OBJECTIVE: To assess whether symptoms of fibromyalgia (FM) predict disability retirement or mortality.
METHODS: All Finnish Twin Cohort members and diagnosed FM-patients who had answered the same health questionnaire in 1990-1992 were studied. A sample of 10,608 working aged individuals of the cohort was classified in homogenous groups based on symptom profile with latent class analysis, using a battery of questions addressing FM-associated symptoms validated between FM-patients and twins. This resulted in three classes: no or few symptoms (LC1), some symptoms (LC2), and high load of FM-symptoms (LC3). In a 14-year follow-up, 1990-2004, information on disability retirement was obtained from official pension registers. Further linkage with Population Register Centre data for 1990-2009 yielded information on the vital status of the cohort subjects. Those with malignancies or inflammatory rheumatic diseases were excluded.
RESULTS: Cumulative incidence of early disability retirement was 9.5% among all 8448 individuals (after exclusions), and 26% in LC3. Adjusted hrs for early retirement were 1.0 (reference class) in LC1, 1.5 (95%CI 1.2-1.7) in LC2, and 2.9 (2.4-3.6) in LC3 for all causes and 1.8 (1.4-2.5) in LC2 and 5.0 (3.6-6.9) in LC3 for musculoskeletal disorders. In 173,675 person-years, the high symptom class (LC3) had a 43% (95% CI 17-75%) increased overall mortality risk, which was fully accounted for by adjustment for lifestyle factors, mainly smoking.
CONCLUSION: Symptoms associated with FM strongly correlate with early disability retirement. Lifestyle problems associated with high symptom load need prompt management to avoid increased risk of mortality.
Copyright © 2011 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21316271     DOI: 10.1016/j.ejpain.2011.01.004

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  7 in total

1.  Severity of symptoms persists for decades in fibromyalgia-a 26-year follow-up study.

Authors:  Risto Isomeri; Marja Mikkelsson; Markku Partinen; Markku J Kauppi
Journal:  Clin Rheumatol       Date:  2018-01-09       Impact factor: 2.980

Review 2.  Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia.

Authors:  Santosh Bhusal; Sherilyn Diomampo; Marina N Magrey
Journal:  Drug Healthc Patient Saf       Date:  2016-02-17

3.  Long-Term Outcome of Bodily Distress Syndrome in Primary Care: A Follow-Up Study on Health Care Costs, Work Disability, and Self-Rated Health.

Authors:  Mette Trollund Rask; Eva Ørnbøl; Marianne Rosendal; Per Fink
Journal:  Psychosom Med       Date:  2017-04       Impact factor: 4.312

4.  Early Retirement: A Meta-Analysis of Its Antecedent and Subsequent Correlates.

Authors:  Gabriela Topa; Marco Depolo; Carlos-Maria Alcover
Journal:  Front Psychol       Date:  2018-01-04

5.  Prognostic factors for work disability in patients with chronic widespread pain and fibromyalgia: protocol for a cohort study.

Authors:  Pernille H Duhn; Henning Locht; Eva Ejlersen Wæhrens; Robin Christensen; Karsten Thielen; Marius Henriksen; Lars Erik Kristensen; Henning Bliddal; Kirstine Amris
Journal:  BMJ Open       Date:  2021-12-22       Impact factor: 2.692

6.  Elevated highly sensitive C-reactive protein in fibromyalgia associates with symptom severity.

Authors:  Teemu Zetterman; Ritva Markkula; Eija Kalso
Journal:  Rheumatol Adv Pract       Date:  2022-06-25

7.  Smoking is associated with reduced leptin and neuropeptide Y levels and higher pain experience in patients with fibromyalgia.

Authors:  Maria I Bokarewa; Malin C Erlandsson; Jan Bjersing; Mats Dehlin; Kaisa Mannerkorpi
Journal:  Mediators Inflamm       Date:  2014-08-14       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.